Endonovo Therapeutics Hires David Clark as Vice President of Sales
03 mai 2019 09h20 HE
|
Endonovo Therapeutics, Inc.
Los Angeles, May 03, 2019 (GLOBE NEWSWIRE) -- Endonovo Therapeutics, Inc. (OTCQB: ENDV), today announced veteran sales leader David Clark joined as Endonovo’s Vice President of Sales. In his new...
Study Finds Variations in Percentage of Clinical Teams Using Simple and Complex Adaptive Trial Designs
04 sept. 2017 19h16 HE
|
Cutting Edge Information
RESEARCH TRIANGLE PARK, NC--(Marketwired - September 04, 2017) - Recent analysis of clinical development teams show that surveyed clinical teams are divided on whether or not companies should...
Clinical Teams From Top Pharma Companies Are Overcoming Challenges in Planning and Implementing Adaptive Trial Design Studies
19 juil. 2017 19h23 HE
|
Cutting Edge Information
RESEARCH TRIANGLE PARK, NC--(Marketwired - July 19, 2017) - A recent study of Top 10, Top 50, and small medical device companies found that addressing regulators' concerns for late-stage studies is...
Centralized Adaptive Trial Design Teams Facilitate Communication Between Global & Country-Level Pharma Teams
22 juin 2017 15h41 HE
|
Cutting Edge Information
RESEARCH TRIANGLE PARK, NC--(Marketwired - June 22, 2017) - The majority of surveyed clinical trial teams -- from those with global responsibility to those positioned at the country level -- report...
Adaptive Design Trials Emerge As Most Popular Method Used By Pharma Companies to Reduce Phase 3 Failures
07 juin 2017 16h27 HE
|
Cutting Edge Information
RESEARCH TRIANGLE PARK, NC--(Marketwired - June 07, 2017) - About 60% of surveyed life science teams believe that using adaptive design trials in early-stage clinical studies increase the odds of...
Study Finds Variations in Percentage of Clinical Teams Using Adaptive Trials and When
11 mai 2017 20h00 HE
|
Cutting Edge Information
RESEARCH TRIANGLE PARK, NC--(Marketwired - May 11, 2017) - There is no one-size-fits-all approach to strategic adaptive trial design use, according a study published by business intelligence firm...
Implementing Risk-Based Approaches During Longer Clinical Trials Maximizes Financial Impact
29 mars 2017 18h54 HE
|
Cutting Edge Information
RESEARCH TRIANGLE PARK, NC--(Marketwired - March 29, 2017) - Life science firms look to risk-based monitoring (RBM) to reduce costs associated with clinical studies, according to a study by business...
Surveyed Top 50 Pharma and Biotech Companies Report Average Per-Patient Costs of $57,500 During Non-Adaptive Phase 1 Studies
27 mars 2017 19h28 HE
|
Cutting Edge Information
RESEARCH TRIANGLE PARK, NC--(Marketwired - March 27, 2017) - Surveyed pharmaceutical, biotech, and device companies expend up to $120,000 per patient during Phase 1 non-adaptive studies, according to...
Pharma Companies Use Social Media to Attract Patients for Clinical Trials
09 févr. 2017 08h13 HE
|
Cutting Edge Information
RESEARCH TRIANGLE PARK, NC--(Marketwired - February 09, 2017) - A study of clinical development teams reveals that 57% of surveyed contract research organizations (CROs) and only 33% of...
3D Signatures Common Shares Now Listed on the OTCQB and Frankfurt Stock Exchanges
04 janv. 2017 07h00 HE
|
3D Signatures Inc.
WINNIPEG, MB--(Marketwired - January 04, 2017) - 3D Signatures Inc. (TSX VENTURE: DXD) (the "Company" or "3DS") is pleased to announce that its common shares have started trading on the OTCQB Venture...